The ESMO Asia 2025 (ESMOAsia25) is taking place from December 5-7, 2025, in Singapore
The congress serves as a vital platform to advance cancer care through the latest scientific discoveries, innovative therapies, and evolving clinical practices. Whether you’re a clinician, researcher, or healthcare provider, this gathering offers a front-row seat to the future of oncology.
Angela Lamarca, Lead of NET HPB and NET Medical Oncologist at Jiménez Díaz Foundation University Hospital and The Christie NHS Foundation Trust, shared some insights from the event:
“Opening ceremony at ESMO Asia 2025 in Singapore
‘Thinking global but acting locally,’ as stated by our current ESMO President Fabrice Andre.
Ready to network, share knowledge, and present our latest day.”
Keynote Lecture by Eileen Poon
“Keynote Lecture by Eileen Poon at ESMOAsia25 on Cancer in Adolescents and Young Adults
Numbers are scary
Financial and social implications too
How will we adjust our practice to this?”
Our data from Jiménez Díaz Foundation and Hospital Clínic
“Our data from Jiménez Díaz Foundation and Hospital Clínic presented at ESMOAsia25
Tumour Growth Rate (TGR) can identify anti-tumour effect with cytostatic agents, where the main response is SD by RECIST.
Example: ivosidenib in Biliary Malignancies.”
“GI Mini Oral Session ESMOAsia25
SIERRA trial with DurvaTreme in non-HIMALAYA population (more fragile)
Asian population: no new safety concerns.”
Discussion by Changhoon Yoo No 2
“GI Mini Oral Session ESMOAsia25
DurvaTreme in HIMALAYA and IpiNivo in CheckMate9DW (1L advanced HCC)
Asian population was presented for both studies
Results confirm activity and safety profile seen in the whole population for both schedules.”
Proffered Paper session at ESMOAsia25
“Proffered Paper session at ESMOAsia25 starts now in Singapore
Abstracts in NET, HCC and BTC coming.”
“Proffered Paper in NET at ESMOAsia25
LUMINET-1 phase III – PRRT (LuDOTATATE x4; NO SSA) vs high dose SSA (2L) in GEP-NET (90%G2) Chinese population
- PFS HR 0.06
- ORR 40% vs 2%; DOR immature
- OS HR 0.17
- Haemat tox
To China: very active
To Western: SSA is NOT a must.”
“Proffered Paper in HCC at ESMOAsia25
MRD (Tumor-informed ctDNA) in Adjuvant HCC
Adj (not randomised – no 49%, yes: TACE 17%/systemic 33%)
At 1 month: ctDNA 44/153 +ve 28.8% -ve 102/153 66.7%
ctDNA is prognostic: RFS/OS and predictive for systemic adj.”
Very interesting discussion by Stephen Chan
“Very interesting discussion by Stephen Chan – ctDNA predicted recurrence only 3.3 months (median time) before imaging did….
My logistics: tumour-informed MRD with ctDNA costs time and money
Ongoing prospective trial in China, Dr Hui Chuan
Am I the only one excited?”
Very interesting discussion on toxicity
“Very interesting discussion on toxicity
Higher (x2-3 times) haemato-toxicity (grade 1/2) in China (LUMINET-1) vs Western (NETTER-1)
Should the dose be the same? Maybe not (I agree, Dr Llang)
Stephen Chan (as usual).”
“Proffered Paper in BTC at ESMOAsia25
TOURMALINE (DurvaChemo nonTOPAZ) in Asia (90 pts)
iCCA51%; GBC30%; PS2 16.7%
52% G3-4 AEs – haem/cholangitis; 13% anyG imAE; 6.7% IRR
26.7% ORR – best CisGem (PS2; ORR 50%)
Confirms data in Asia
Doublet (vs mono) chemo best.”
My take-home message from TOURMALINE
“My take-home message from TOURMALINE at ESMOAsia25
Gem-alone underperforms vs doublet (agreed Dr Chan)
BUT…
CisGemDurva in PS2 from Global population (n=18) SIMILAR to TOPAZ (3-4).”
“Here we are, a few of the GI people at ESMOAsia25
It’s always a pleasure working with you all.
Great co-chairing of the ESMO Asia conference, Dr Oh
Fantastic track chairs, Lorenza Rimassa and Dr Ikeda
To many more of these…”
You can find more posts from ESMO Asia 2025 on OncoDaily.